XEN1701
Pain
Phase 1Clinical trial initiated
Key Facts
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is a Canadian biotech leader dedicated to developing life-changing medicines for neurological and psychiatric conditions. Its core strategy leverages a validated human genetics platform to de-risk ion channel drug discovery, resulting in a deep pipeline of 23 candidates, most notably the Phase 3 Kv7 opener azetukalner for epilepsy and depression. With a market cap of $5.23B and a seasoned leadership team, Xenon is transitioning from a discovery-focused entity to a late-stage clinical company with significant near-term catalysts.
View full company profileTherapeutic Areas
Other Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Desmetramadol | Syntrix Pharmaceuticals | Clinical Development |
| Diclofenac Potassium Powder for Oral Solution | Patrin Pharma | Approved |
| CG001419 | Cullgen | Phase 1 |
| Proprietary Pain Program(s) | Oblique Therapeutics | Pre-clinical |
| Pain Management APIs | Noramco | Commercial |
| Dipendium (Diclofenac Potassium) | NovaMedica | Approved |
| Na ion channel TicTACs | Solu Therapeutics | Preclinical |
| Infusional Pain Management (e.g., Paracetamol) | Galenica Senese | Commercial |
| NCEs for Pain Management | Ipca Laboratories | Preclinical/Discovery |